Insulin Regulation of MCP-1 in Human Adipose Tissue of Obese and Lean Women
Overview
Physiology
Authors
Affiliations
CCL2 (MCP-1, monocyte chemoattractant protein 1) and CCL3 (MIP-1alpha, macrophage inflammatory protein 1alpha) are required for macrophage infiltration in adipose tissue. Insulin increases CCL2 expression in adipose tissue and in serum more in insulin-resistant obese than in insulin-sensitive lean mice, but whether this is true in humans is unknown. We compared basal expression and insulin regulation of CCL2 and CCL3 in adipose tissue and MCP-1 and MIP-1alpha in serum between insulin-resistant and insulin-sensitive human subjects. Subcutaneous adipose tissue biopsies and blood samples were obtained before and at the end of 6 h of in vivo euglycemic hyperinsulinemia (maintained by the insulin clamp technique) in 11 lean insulin-sensitive and 10 obese insulin-resistant women, and before and after a 6-h saline infusion in 8 women. Adipose tissue mRNA concentrations of monocyte/macrophage markers CD68, EMR1, ITGAM, ADAM8, chemokines CCL2 and CCL3, and housekeeping gene ribosomal protein large P0 (RPLP0) were measured by means of real-time PCR at baseline. In addition, mRNA concentrations of CCL2, CCL3, and RPLP0 were measured after insulin infusion. Levels of MCP-1 and MIP-1alpha were determined in serum, and protein concentration of MCP-1 was determined in adipose tissue at baseline and after insulin infusion. Basally, expression of the macrophage markers CD68 and EMR1 were increased in adipose tissue of insulin-resistant subjects. Insulin increased MCP-1 gene and protein expression significantly more in the insulin-resistant than in the insulin-sensitive subjects. Basally expression of CCL2 and CCL3 and expression of macrophage markers CD68 and ITGAM were significantly correlated. In serum, MCP-1 decreased significantly in insulin-sensitive but not insulin-resistant subjects. MIP-1alpha was undetectable in serum. Insulin regulation of CCL2 differs between insulin-sensitive and -resistant subjects in a direction that could exacerbate adipose tissue inflammation.
Chen H, Zhang G, Zhou X World J Diabetes. 2024; 15(2):170-185.
PMID: 38464370 PMC: 10921168. DOI: 10.4239/wjd.v15.i2.170.
Cooper I, Kyriakidou Y, Edwards K, Petagine L, Seyfried T, Duraj T Int J Mol Sci. 2023; 24(21).
PMID: 37958602 PMC: 10650498. DOI: 10.3390/ijms242115621.
Ren Y, Zhao H, Yin C, Lan X, Wu L, Du X Front Endocrinol (Lausanne). 2022; 13:873699.
PMID: 35909571 PMC: 9329830. DOI: 10.3389/fendo.2022.873699.
Verdu E, Homs J, Boadas-Vaello P Int J Environ Res Public Health. 2021; 18(24).
PMID: 34948944 PMC: 8705491. DOI: 10.3390/ijerph182413333.
Balcazar-Hernandez L, Basurto L, Manuel-Apolinar L, Vega-Garcia S, Basurto-Acevedo N, Martinez-Murillo C Metabolites. 2021; 11(11).
PMID: 34822430 PMC: 8619823. DOI: 10.3390/metabo11110771.